AUTHORS
Andrew J. Yee, MD, Rafael Fonseca, MD2, Yael C. Cohen, MD3, Andrzej J. Jakubowiak, MD, PhD4, Keith Stewart, MD5, Christopher Strouse, MD6, Yi Lin Jr, MD, PhD7, Thomas Martin, MD8, Leyla Shune, MD9, Nina Benachour10, Arnab Ghosh, MD, PhD11, Carolina Lonardi, PharmD12, Tamar Lengil, PhD13, Katherine Li, MS14, Ana Slaughter15, Deepu Madduri, MD16, Chris Del Corral17, Nitin Patel18, Vrinda Mahajan19, Dominik Dytfeld, MD, PhD20, Tadao Ishida, MD, PhD21, Seok Jin Kim, MD, PhD22, Cyrille Touzeau Sr, MD, PhD23
AFFILIATIONS
1 Harvard Medical School, Boston, Massachusetts, United States
2 Mayo Clinic, Phoenix, Arizona, United States
3 Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel, Tel Aviv University, Tel Aviv, Israel
4 University of Chicago, Chicago, Illinois, United States
5 University Health Network and the Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 University of Iowa, Iowa City, Iowa, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
9 Indiana Blood & Marrow Transplantation, Indianapolis, Indiana, United States
10 Johnson & Johnson, Beerse, Belgium
11 Johnson & Johnson, Raritan, New Jersey, United States
12 Johnson & Johnson, Buenos Aires, Argentina
13 Johnson & Johnson, Raritan, New Jersey, United States
14 Johnson & Johnson, Spring House, Pennsylvania, United States
15 Johnson & Johnson, Zug, Switzerland
16 Johnson & Johnson, Raritan, New Jersey, United States
17 Legend Biotech USA Inc, Somerset, New Jersey, United States
18 Legend Biotech USA Inc, Somerset, New Jersey, United States
19 Legend Biotech USA Inc, Somerset, New Jersey, United States
20 Poznan University of Medical Sciences, Poznan, Poland
21 Japanese Red Cross Medical Center, Tokyo, Japan
22 Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
23 CHU Hotel Dieu, Nantes, France
ABSTRACT
Introduction: In the phase 3 study CARTITUDE-4 (NCT04181827), at a median follow-up of 33.6 months (mo), cilta-cel significantly improved progression-free survival (PFS) (weighted hazard ratio [HR], 0.29; 95% CI, 0.22-0.39) and overall survival (OS) (HR, 0.55; 95% CI, 0.39-0.79; P=0.0009) versus standard of care (SOC) in patients (pts) with lenalidomide-refractory, relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, based on the intent-to-treat (ITT) analysis (Einsele et al. Lancet Oncol. 2026). In CARTITUDE-4, 25.1% (105/419) of pts were daratumumab (dara)-exposed and 22.2% (93/419) were dara-refractory. Previously reported CARTITUDE-4 subgroup analyses in the ITT population demonstrated significantly improved PFS vs SOC in dara-naïve pts with a weighted HR of 0.31 (95% CI, 0.22-0.44) and in dara-exposed pts with a weighted HR of 0.24 (95% CI, 0.14-0.42). Long-term follow-up of a similar population in CARTITUDE-2 cohort A found that 50% (5/10) of the patients who were treatment and disease-free 5 years after a single cilta-cel infusion were dara-refractory (Cohen et al. IMS 2026, poster PA-59). We report CARTITUDE-4 subgroup analyses of PFS and OS based on dara exposure and refractory status in pts who received cilta-cel as study treatment.
Methods: In CARTITUDE-4 (San-Miguel et al. N Engl J Med. 2023), lenalidomide-refractory pts with 1-3 prior lines of therapy were assigned 1:1 to cilta-cel or SOC (investigator’s choice of pomalidomide, bortezomib, and dexamethasone [PVd] or dara, pomalidomide, and dexamethasone [DPd]). Pts in the cilta-cel arm underwent apheresis, received at least 1 cycle of bridging therapy with either PVd or DPd (based on investigator’s choice), lymphodepletion, and then a single cilta-cel infusion (at a target dose of 0.75×106 CAR+ viable T cells/kg) 5-7 days after the start of lymphodepletion. PFS, assessed using a validated computerized algorithm, and OS were analyzed in randomized pts who received cilta-cel infusion as study treatment, with both end points measured from the time of cilta-cel infusion.
Results: In the cilta-cel as-treated population (n=176), 33 (18.8%) were dara-refractory and 3 (1.7%) were dara-exposed but not refractory. All 33 dara-refractory pts were triple-class-exposed and 19 of them (57.6%) were triple-class-refractory. Among the 33 pts who were dara-refractory, the median time from initial multiple myeloma diagnosis to initiation of prior dara treatment was 24.6 mo; median duration of prior dara treatment was 11.1 mo; median time from last dara treatment before apheresis was 1.9 mo. Of these 33 pts who were dara-refractory, 16 (48.5%) received dara as part of DPd bridging therapy on study and their responses were VGPR (n=2), PR (n=3), MR (n=1), and SD (n=10). In the dara-naive group, the 30-mo PFS rate was 70.2% (95% CI, 61.6-77.3). In the dara-refractory group, the 18-mo PFS was 66.7 (95% CI, 47.9-80.0) and the 30-mo PFS was 57.6% (95% CI, 39.1-72.3), with 15 events (45.5%). Notably, the median OS was not reached in either subgroup, with 30-mo OS rates of 86.7% (95% CI, 79.7-91.4) in the dara-naive group and 72.7% (95% CI, 54.1-84.8) in the dara-refractory group (9 events; 27.3%).
Conclusions: As anti-CD38–containing regimens are increasingly used earlier in treatment, a growing proportion of pts become dara-refractory, a population characterized by poor outcomes. In CARTITUDE-4, pts with lenalidomide- and dara-refractory RRMM achieved durable outcomes after cilta-cel infusion, with nearly 60% remaining progression-free at 30 mo and a median OS was not reached. These results are noteworthy given the extent to which the disease was refractory to dara (median time to progression on prior dara <1 year) and that nearly half of pts were limited to dara-based bridging therapy on study. In this hard-to-treat population, a single cilta-cel infusion resulted in prolonged treatment-free remission. These findings show the clinically meaningful efficacy of cilta-cel as early as the second-line setting regardless of prior CD38 exposure or refractory status and support its use in patients with lenalidomide- and daratumumab-refractory multiple myeloma.
DISCLOSURES
Andrew J. Yee, MD: Sanofi - Research Funding; Takeda - Research Funding; Amgen - Research Funding; Johnson & Johnson - Research Funding; BMS - Research Funding; GSK - Research Funding; Pfizer - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Sebia - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)